<DOC>
	<DOCNO>NCT00395486</DOCNO>
	<brief_summary>The primary objective study compare effect rosuvastatin 10mg atorvastatin 10mg 6 week treatment ratio ApoB/ApoA1 subject metabolic syndrome .</brief_summary>
	<brief_title>ROMEO ( Rosuvastatin Metabolic syndrOme )</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Metabolic Syndrome X</mesh_term>
	<mesh_term>Atorvastatin Calcium</mesh_term>
	<mesh_term>Rosuvastatin Calcium</mesh_term>
	<criteria>Presence 3 follow criterion ; Abdominal obesity ( men &gt; 90cm woman &gt; 80cm ) Triglycerides ≥ 150 mg/dL HDLC : men &lt; 40 mg/dL , woman &lt; 50 mg/dL BP ≥130/≥85 mmHg antihypertensive treatment Fasting blood glucose ≥100 mg dL antidiabetic treatment Elevated LDLC ; ≥130 mg/dL &lt; 220 mg/dL lipid lower agent naive subject ≥100 mg/dL &lt; 200 mg/dL subject take lipid lowering drug ( ) within 4 week visit 1 . Triglyceride &lt; 500 mg/dL</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>rosuvastatin</keyword>
	<keyword>lipoprotein</keyword>
	<keyword>metabolic syndrome</keyword>
</DOC>